TOP 1705 (Non Small Cell Lung Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out how safe the study drug combination of Nivolumab, Ipilimumab, and Paclitaxel is for people with non small cell lung cancer and if this combination will work.

What is the Condition Being Studied?

Non Small Cell Lung Cancer (NSCLC)

Who Can Participate in the Study?

Adults 18 years or older with Stage IV or recurrent NSCLC with no prior treatment

Age Group

What is Involved?

If you choose to join this study, you will:
- Get chemotherapy and immunotherapy
- Have blood samples and possibly a small piece of tissue removed from your lung to see what type of lung cancer cells you have
- Have other tests, exams, and procedures for study purposes and your standard of care
- Be in the study for up to 24 months after the start of study drug or until your condition worsens or you have unbearable side effects

Study Details

Full Title
A Phase II Clinical Trial of Combination Nivolumab (Opdivo), Ipilimumab (Yervoy), and Paclitaxel in Patients with Untreated Metastatic Non Small Cell Lung Cancer (NSCLC) (The OPTIMAL Trial) [TOP 1705]
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00092210
NCT: NCT03573947
Phase II
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center